JP2021502824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502824A5 JP2021502824A5 JP2020544356A JP2020544356A JP2021502824A5 JP 2021502824 A5 JP2021502824 A5 JP 2021502824A5 JP 2020544356 A JP2020544356 A JP 2020544356A JP 2020544356 A JP2020544356 A JP 2020544356A JP 2021502824 A5 JP2021502824 A5 JP 2021502824A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- optionally substituted
- disease
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 53
- 239000000203 mixture Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 208000035475 disorder Diseases 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 201000001981 dermatomyositis Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 210000000130 stem cell Anatomy 0.000 claims 7
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 5
- 101710163270 Nuclease Proteins 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 229940123517 Aryl hydrocarbon receptor antagonist Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- -1 C1-4 alkyl hydrogen Chemical compound 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 241000251730 Chondrichthyes Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 206010061979 Genital pain Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025280 Lymphocytosis Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 240000007019 Oxalis corniculata Species 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 208000010346 Sphingolipidoses Diseases 0.000 claims 1
- 201000001307 Sphingolipidosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010069776 Thrombocytoses Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 208000007345 glycogen storage disease Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000002997 osteoclast Anatomy 0.000 claims 1
- 208000002865 osteopetrosis Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579803P | 2017-10-31 | 2017-10-31 | |
| US62/579,803 | 2017-10-31 | ||
| US201762596676P | 2017-12-08 | 2017-12-08 | |
| US62/596,676 | 2017-12-08 | ||
| US201862613383P | 2018-01-03 | 2018-01-03 | |
| US62/613,383 | 2018-01-03 | ||
| US201862625917P | 2018-02-02 | 2018-02-02 | |
| US62/625,917 | 2018-02-02 | ||
| US201862634638P | 2018-02-23 | 2018-02-23 | |
| US62/634,638 | 2018-02-23 | ||
| US201862747068P | 2018-10-17 | 2018-10-17 | |
| US62/747,068 | 2018-10-17 | ||
| PCT/US2018/058553 WO2019089826A1 (en) | 2017-10-31 | 2018-10-31 | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502824A JP2021502824A (ja) | 2021-02-04 |
| JP2021502824A5 true JP2021502824A5 (https=) | 2021-12-09 |
| JP7412341B2 JP7412341B2 (ja) | 2024-01-12 |
Family
ID=64317009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544356A Active JP7412341B2 (ja) | 2017-10-31 | 2018-10-31 | 造血幹細胞および前駆細胞の増幅のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190314407A1 (https=) |
| EP (1) | EP3704232A1 (https=) |
| JP (1) | JP7412341B2 (https=) |
| CN (1) | CN111542597A (https=) |
| AU (1) | AU2018358241A1 (https=) |
| CA (1) | CA3079405A1 (https=) |
| WO (1) | WO2019089826A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3177929A1 (en) | 2012-12-21 | 2014-06-26 | Astellas Institute For Regenerative Medicine | Methods for production of platelets from pluripotent stem cells and compositions thereof |
| MX392743B (es) | 2017-04-12 | 2025-03-12 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
| WO2019036657A1 (en) | 2017-08-17 | 2019-02-21 | Kyn Therapeutics | AHR INHIBITORS AND USES THEREOF |
| JP2021509812A (ja) | 2018-01-05 | 2021-04-08 | プレートレット バイオジェネシス， インコーポレイテッド | 巨核球を産生するための組成物および方法 |
| AU2019291955A1 (en) | 2018-06-29 | 2021-02-18 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| CN111187262A (zh) * | 2020-01-21 | 2020-05-22 | 沈阳药科大学 | 咪唑并[1,2-a]吡啶衍生物及其制备方法和应用 |
| CN118844386A (zh) * | 2024-07-22 | 2024-10-29 | 武汉合研生物医药科技有限公司 | 一种表达人免疫细胞的小鼠特应性皮炎模型的构建方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US5233044A (en) | 1989-06-08 | 1993-08-03 | Millipore Corporation | Active esters for solid phase peptide synthesis |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US5512421A (en) | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| DE69433301T2 (de) | 1993-06-08 | 2004-09-09 | Smithkline Beecham Corp. | Methoden zur erhöhung der biologischen aktivität von chemokinen |
| US6447766B1 (en) | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US5547892A (en) | 1995-04-27 | 1996-08-20 | Taiwan Semiconductor Manufacturing Company | Process for forming stacked contacts and metal contacts on static random access memory having thin film transistors |
| US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US5801030A (en) | 1995-09-01 | 1998-09-01 | Genvec, Inc. | Methods and vectors for site-specific recombination |
| HU226994B1 (en) | 1997-02-11 | 2010-04-28 | Mallinckrodt | Reactor and method for solid phase peptide synthesis |
| EP1068357B2 (en) | 1998-03-30 | 2014-12-10 | NorthWest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| DE60042030D1 (de) | 1999-12-17 | 2009-05-28 | Genzyme Corp | Chemokinrezeptor-bindende heterocyclische verbindungen |
| CA2407651C (en) | 2000-04-27 | 2013-07-02 | Max-Delbruck-Centrum Fur Molekulare Medizin | Sleeping beauty, a transposon vector with a broad host range for the genetic transformation in vertebrates |
| DE60103052T2 (de) | 2000-05-09 | 2005-03-03 | The University Of British Columbia, Vancouver | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten |
| CA2412436C (en) | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| CA2456977C (en) | 2001-08-16 | 2011-06-07 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| JP2008509928A (ja) | 2004-08-13 | 2008-04-03 | アノーメド インコーポレイテッド | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
| RU2008102646A (ru) | 2005-06-24 | 2009-07-27 | Риджентс Оф Дзе Юниверсити Оф Миннесота (Us) | Применение цитозиндезаминаз для уменьшения переноса ретроэлементов от свиней человеку |
| CA2891996A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| KR20090021217A (ko) | 2006-06-14 | 2009-02-27 | 추가이 세이야쿠 가부시키가이샤 | 조혈 줄기세포 증가 촉진제 |
| EP1995316A1 (de) | 2007-05-25 | 2008-11-26 | Qiagen GmbH | Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen |
| EP2009095A1 (en) | 2007-06-28 | 2008-12-31 | Innovalor AG | Method of generating glucose-responsive cells |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010085699A2 (en) | 2009-01-23 | 2010-07-29 | The Johns Hopkins University | Mammalian piggybac transposon and methods of use |
| EP2270025A1 (en) | 2009-06-29 | 2011-01-05 | Centre National pour la Recherche Scientifique (CNRS) | Solid phase peptide synthesis of peptide alcohols |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| BR112012020257A8 (pt) | 2010-02-11 | 2018-02-14 | Recombinetics Inc | métodos e aparelhos para produzir artiodátilos transgênicos |
| CA2821834A1 (en) * | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| US9284317B2 (en) * | 2010-12-17 | 2016-03-15 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors |
| JP2013545779A (ja) * | 2010-12-17 | 2013-12-26 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン |
| BR112013021785A8 (pt) | 2011-02-25 | 2018-07-03 | Recombinetics Inc | animais geneticamente modificados e métodos para fazer os mesmos |
| US9388212B2 (en) | 2013-02-21 | 2016-07-12 | Chemical & Biopharmaceutical Laboratories Of Patras S.A. | Solid phase peptide synthesis via side chain attachment |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| JP2016516672A (ja) * | 2013-02-28 | 2016-06-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 幹細胞を動員するための方法および組成物 |
| US9169287B2 (en) | 2013-03-15 | 2015-10-27 | Massachusetts Institute Of Technology | Solid phase peptide synthesis processes and associated systems |
| US10117899B2 (en) * | 2013-10-17 | 2018-11-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| US9816074B2 (en) * | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| HUE055583T2 (hu) * | 2014-09-16 | 2021-12-28 | Sangamo Therapeutics Inc | Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben |
| WO2017161001A1 (en) * | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| MX392743B (es) * | 2017-04-12 | 2025-03-12 | Magenta Therapeutics Inc | Antagonistas del receptor de hidrocarburo de arilo y sus usos. |
-
2018
- 2018-10-31 EP EP18803842.6A patent/EP3704232A1/en not_active Withdrawn
- 2018-10-31 WO PCT/US2018/058553 patent/WO2019089826A1/en not_active Ceased
- 2018-10-31 JP JP2020544356A patent/JP7412341B2/ja active Active
- 2018-10-31 CA CA3079405A patent/CA3079405A1/en active Pending
- 2018-10-31 AU AU2018358241A patent/AU2018358241A1/en not_active Abandoned
- 2018-10-31 CN CN201880084804.0A patent/CN111542597A/zh active Pending
- 2018-10-31 US US16/177,252 patent/US20190314407A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502824A5 (https=) | ||
| Poggi et al. | How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive | |
| Jian et al. | The involvement and therapy target of immune cells after ischemic stroke | |
| ES2907581T3 (es) | Método mejorado para la generación de células genéticamente modificadas | |
| Taylor et al. | Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD) | |
| US20220033856A1 (en) | Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies | |
| CN113509482A (zh) | Dna四面体在制备预防和治疗舍格伦综合征的药物中的用途 | |
| Sotiropoulou et al. | Immune properties of mesenchymal stem cells | |
| Bacigalupo et al. | Haploidentical donor transplants for severe aplastic anemia | |
| Thompson et al. | Umbilical cord blood graft engineering: challenges and opportunities | |
| Fox et al. | Gene therapy for primary immunodeficiencies | |
| US20220168393A1 (en) | Il-12 compositions and methods of use in hematopoietic recovery | |
| JP2021505172A5 (https=) | ||
| Pochon et al. | Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation | |
| Monteiro et al. | iNKT cells: innate lymphocytes with a diverse response | |
| IL274632B2 (en) | Methods and compositions for non-myeloablative bone marrow reconstitution | |
| WO2021232014A2 (en) | Compositions, systems, and methods for generating gene-edited cells | |
| CA3173425A1 (en) | Mitochondrial augmentation therapy | |
| CN112040960A (zh) | 修饰免疫细胞以增加活性 | |
| JP2012532624A5 (https=) | ||
| CA3177093A1 (en) | Methods for targeted insertion of exogenous sequences in cellular genomes | |
| CN112135618A (zh) | 体内介导免疫应答的nk和dc细胞的扩增 | |
| JP2021503008A5 (https=) | ||
| Buza-Vidas et al. | Crucial role of FLT3 ligand in immune reconstitution after bone marrow transplantation and high-dose chemotherapy | |
| Najima et al. | Mesenchymal stem cells: the first approved stem cell drug in Japan |